RNAi Therapeutics Market Revenue 2024 to 2034
RNAi Therapeutics Market Revenue 2024 to 2034
The RNAi therapeutics market is forecast to grow at a CAGR of 14.9%, from USD 1.47 billion in 2025 to USD 5.11 billion by 2034, over the forecast period from 2025 to 2034.
Report ID: 10157
|
Format: Databook
|
Published: August 2025
|
Delivery: Immediate
Download Sample
Customisation Request
Revenue,
USD USD 1.28 Bn
Forecast Year,
USD USD 5.11 Bn
CAGR, 2025 -
64%
Report Coverage
Worldwide
Reviewed By
Aditi Shivarkar
Reviewed By
Aman Singh
RNAi Therapeutics Market Size Analysis
RNAi Therapeutics Market Size By Type 2024 to 2034 (USD )
| Type | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| siRNA | 832.00 | 958.91 | 1105.17 | 1273.72 | 1467.97 | 1691.82 | 1949.79 | 2247.08 | 2589.67 | 2984.47 | 3439.42 |
| miRNA | 448.00 | 511.81 | 584.69 | 667.93 | 762.99 | 871.54 | 995.51 | 1137.08 | 1298.72 | 1483.30 | 1694.04 |
RNAi Therapeutics Market Size By Application 2024 to 2034 (USD )
| Application | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oncology | 512.00 | 592.70 | 686.08 | 794.13 | 919.15 | 1063.80 | 1231.14 | 1424.73 | 1648.68 | 1907.74 | 2207.39 |
| Cardiovascular Disease | 153.60 | 175.75 | 201.09 | 230.09 | 263.25 | 301.20 | 344.60 | 394.25 | 451.05 | 516.03 | 590.35 |
| Infectious Disease | 192.00 | 222.08 | 256.86 | 297.07 | 343.57 | 397.32 | 459.47 | 531.31 | 614.37 | 710.37 | 821.35 |
| Diabetes | 102.40 | 118.39 | 136.88 | 158.24 | 182.94 | 211.48 | 244.46 | 282.58 | 326.63 | 377.53 | 436.34 |
| Neurology | 192.00 | 222.81 | 258.55 | 299.98 | 348.03 | 403.73 | 468.30 | 543.16 | 629.92 | 730.48 | 847.02 |
| Other Applications | 128.00 | 138.98 | 150.40 | 162.13 | 174.01 | 185.84 | 197.34 | 208.13 | 217.75 | 225.62 | 231.01 |
RNAi Therapeutics Market Size By Development Stage 2024 to 2034 (USD )
| Development Stage | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Preclinical Research | 640.00 | 730.95 | 834.79 | 953.35 | 1088.70 | 1243.23 | 1419.64 | 1621.01 | 1850.88 | 2113.25 | 2412.73 |
| Clinical Trials | 448.00 | 517.69 | 598.21 | 691.23 | 798.68 | 922.81 | 1066.20 | 1231.83 | 1423.15 | 1644.14 | 1899.38 |
| Approved Drugs | 192.00 | 222.08 | 256.86 | 297.07 | 343.57 | 397.32 | 459.47 | 531.31 | 614.37 | 710.37 | 821.35 |
RNAi Therapeutics Market Size By Region 2024 to 2034 (USD )
| Region | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | 486.40 | 555.93 | 635.39 | 726.18 | 829.91 | 948.44 | 1083.87 | 1238.60 | 1415.38 | 1617.33 | 1848.05 |
| Europe | 332.80 | 382.39 | 439.36 | 504.83 | 580.05 | 666.47 | 765.78 | 879.88 | 1010.98 | 1161.62 | 1334.70 |
| Asia-Pacific | 281.60 | 327.24 | 380.22 | 441.72 | 513.12 | 595.98 | 692.15 | 803.74 | 933.21 | 1083.43 | 1257.70 |
| Latin America | 102.40 | 116.92 | 133.50 | 152.42 | 174.01 | 198.66 | 226.79 | 258.89 | 295.52 | 337.32 | 385.01 |
| Middle East & Africa | 76.80 | 88.24 | 101.39 | 116.50 | 133.86 | 153.80 | 176.72 | 203.05 | 233.30 | 268.07 | 308.01 |
RNAi Therapeutics Market
Proceed To Buy
Proceed To CheckoutMake Every Move Strategic. Get Insights, Fully Customized
- On-Demand Metrics & KPIs
- Industry-Specific Dashboards
- Quick Turnaround, No Compromises
Quick Contact
- NA : +1 804 441 9344
- APAC : +91 9356 9282 04
- EU : +44 7782 560 738
- sales@precedenceresearch.com
